You are here

"Very Encouraging" Results for Oncolytic Immunotherapies in Melanoma

Robert Andtbacka of the University of Utah provides an overview about “very encouraging” studies of oncolytic immunotherapies in melanoma, such as talimogene laherparepvec and coxsackievirus A21. Both injected and non-injected lesions have responded to this approach.

11th International Congress of the Society for Melanoma Research, November 2014